Septerna, Inc. - 8-K Filing

Septerna selects SEP-204 as development candidate for Graves’ disease and TED with Phase 1 clinical trial planned for Q1 2027. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 4, 2026, 13:15 UTC

Tickers: $SEPN

Read the full article at SEC EDGAR

Part of the story Septerna, Inc. - 8-K Filing (3 articles)

More Regulatory news

Ondas Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:24 UTC
CLARIVATE PLC - 8-K Filing SEC EDGAR · November 12, 2026, 13:24 UTC
CorMedix Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:21 UTC
Corvex, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:21 UTC
Leatt Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:20 UTC
Leatt Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 13:18 UTC
FILANA THERAPEUTICS, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 13:18 UTC
RUM Group Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:17 UTC
Theriva Biologics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SeaStar Medical Holding Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC